SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (118)8/24/2000 7:52:12 AM
From: Micawber  Respond to of 447
 
August 24, 2000

Biotech Industry Flexes New Muscle

Investors Pump Cash Into Research
By ANDREW POLLACK


As a young biotechnology company in 1986, OSI Pharmaceuticals agreed to use its expertise in genes and molecular biology to help Pfizer Inc. discover new drugs for cancer. As in many such deals, OSI agreed to receive a royalty of about 5 percent on the sales of any drugs that made it to market.

nytimes.com



To: scaram(o)uche who wrote (118)9/13/2000 8:48:25 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 447
 
Message 14374630